“Indian pharma companies are building a strong product portfolio for post-2020. From a 12-18 months perspective, the sector looks good.” “We are seeing a turnaround for pharma? in India. For ?emerging markets, the big issue was currency. With the currency stabilizing, markets are growing ?at 15-20 ...
Read more: $23 billion fund sees more gains in costly Indian developers